Risk management actions following genetic testing in the Cancer Health Assessments Reaching Many (CHARM) Study: A prospective cohort study.
Boya GuoSarah A KnerrTia L KauffmanKathleen F MittendorfErin KeastMarian J GilmoreHeather Spencer FeigelsonFrances L LynchKristin R MuessigSonia OkuyamaJamilyn M ZeppDavid L VeenstraLi HsuAmanda I PhippsSara LindströmMichael C LeoKatrina A B GoddardBenjamin S WilfondBeth Devinenull nullPublished in: Cancer medicine (2023)
Though the number of participants who received actionable risk management recommendations was small, our results suggest that implementing CHARM's risk assessment and testing model increased access to evidence-based genetic services and provided opportunities for patients to engage in recommended preventive care, without encouraging risk management overuse.
Keyphrases
- healthcare
- risk assessment
- end stage renal disease
- public health
- ejection fraction
- mental health
- primary care
- palliative care
- chronic kidney disease
- gene expression
- squamous cell carcinoma
- human health
- papillary thyroid
- dna methylation
- genome wide
- heavy metals
- climate change
- pain management
- copy number
- health promotion